TNF-related weak inducer of apoptosis (TWEAK) signaling pathway (WP2036)
TNF related weak inducer of apoptosis (TWEAK) is a small pleiotropic cytokine of the TNF super family and its gene is located at chromosome 17p13.1. TWEAK has been reported to be expressed in tissues that include heart, brain, kidney and also in mononuclear blood cells. The multiple biological activities of TWEAK include stimulation of cell growth and angiogenesis, induction of inflammatory cytokines, and stimulation of apoptosis. It has been shown to be involved in the induction of cellular proliferation in liver cells, osteoblasts, astrocytes, synoviocytes, kidney cells and skeletal muscles. Furthermore, TWEAK plays a substantial role in cellular differentiation in osteoclasts. TWEAK induces glioma cell survival via imparting resistance to cytotoxic agents. It imparts its downstream signaling events by binding to its receptor, FGF inducible 14 protein (Fn14). Two modes of TWEAK-Fn14 (ligand-receptor) interactions have been proposed (i) the ligand dependent interaction which involves the higher concentration of homotrimeric TWEAK, that binds to low concentration of Fn14 in a heterohexameric complex (ii) ligand-independent interaction when the ligand concentration is lower than the receptor concentration which induces the ligand independent interaction. The receptors homotrimerize to activate the downstream events. The signaling cascades reported under TWEAK-Fn14 interactions are the canonical and noncanonical NF-κB pathways and the MAPK pathway. There has been a report on crosstalk between Wnt and TWEAK pathways. In myoblasts the PI3K-AKT module has been reported to be inhibited under TWEAK stimulus. AKT phosprorylation leads to the activation of GSK3β resulting in increase of phospho-GSk3β and active β-catenin1 (CTNNB1) (dephosphorylated) levels. GSK3β and β-catenin1 remain associated in the cytoplasm, phosphorylation of GSK3β leads to the dissociation of β-catenin1 (dephosphorylated) resulting in the nuclear translocation of the protein. Despite of reports on TWEAK binding to other receptors including CD163 and DR3 the downstream events following the binding is yet to be established. The data provided by us would foster enormous avenues for further studies on TWEAK associated proteins and the related disorders such as cancer and autoimmune diseases. The data would enable therapeutic studies by selecting the pathological events and the simultaneous production of blocking agents. Despite the minimal amount of data, ours can also be used in the overlay of various high throughput data enabling pathway analysis and can be accessed by any pathway resource to generate a customized pathway. Please access this pathway at [http://www.netpath.org/netslim/tweak_pathway.html NetSlim] database. If you use this pathway, please cite Bhattacharjee2012 paper (see below). Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP2036 CPTAC Assay Portal].
AuthorsKristina Hanspers , NetPath , Daniela Digles , Alex Pico , Zahra Roudbari , Marianthi Kalafati , Chris Evelo , Egon Willighagen , and Eric Weitz
Discuss this pathway
- Investigating the Molecular Processes behind the Cell-Specific Toxicity Response to Titanium Dioxide Nanobelts (2021).
- Global polysome analysis of normal and injured podocytes (2019).
- A Bioinformatics Resource for TWEAK-Fn14 Signaling Pathway (2012).
- Tissue-specific pathway activities: A retrospective analysis in COVID-19 patients (2022).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Pathway Ontologytumor necrosis factor superfamily mediated signaling pathway